Skip to main content
March 29, 2016
Cell MedX Corp. has announced that it has engaged Nutrasource to commence clinical trials of its innovative and proprietary technology branded under the trade name eBalance.
The intent of the upcoming trial is to assess and quantify eBalance's ability to alter key metabolic pathways targeting improved blood sugar control. The trial will be conducted at several sites across Canada, after review and approval from Health Canada and a central Research Ethics Board (REB).
Cell MedX President and CEO, Mr. Frank McEnulty, commented: "We are very excited to engage Nutrasource to conduct clinical trials for us in Canada, as our ongoing observational studies have shown that our eBalance technology has had positive effect on pain management as well as complications associated with diabetes."
View the full press release here.